Randomized clinical trials have shown that tirzepatide and semaglutide both have shown effectiveness in reducing weight in type 2 diabetes patients; however, comparisons between these two drugs in populations with overweight or obesity are not yet available. This cohort study aimed to compare weight loss and gastrointestinal adverse events in adults with overweight or obesity treated with semaglutide or tirzepatide, irrespective of type 2 diabetes status. The study included 18,386 propensity score-matched patients, of which 55.9% continued with tirzepatide and 52.5% with semaglutide.
Patients on tirzepatide were more likely to achieve significant weight loss, and weight loss was greater with tirzepatide at 3 months (2.4%), 6 months (4.3%), and 12 months (6.9%) than semaglutide. Gastrointestinal adverse events rates were similar between the two groups. The study concluded that…
